Temsirolimus and Bevacizumab in Treating Patients With Advanced Endometrial, Ovarian, Liver, Carcinoid, or Islet Cell Cancer

Summary

This phase II trial studies how well temsirolimus and bevacizumab work in treating patients with advanced endometrial, ovarian, liver, carcinoid, or islet cell cancer. Temsirolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Bevacizumab may also stop the growth of cancer by blocking blood flow to the tumor. Giving temsirolimus together with bevacizumab may kill more tumor cells.

Conditions

• Adult Hepatocellular Carcinoma
• Advanced Adult Hepatocellular Carcinoma
• Endometrial Serous Adenocarcinoma
• Localized Non-Resectable Adult Liver Carcinoma
• Lung Carcinoid Tumor
• Malignant Pancreatic Gastrinoma
• Malignant Pancreatic Glucagonoma
• Malignant Pancreatic Insulinoma
• Malignant Pancreatic Somatostatinoma
• Metastatic Digestive System Neuroendocrine Tumor G1
• Ovarian Carcinosarcoma
• Ovarian Endometrioid Adenocarcinoma
• Ovarian Seromucinous Carcinoma
• Ovarian Serous Surface Papillary Adenocarcinoma
• Pancreatic Alpha Cell Adenoma
• Pancreatic Beta Cell Adenoma
• Pancreatic Delta Cell Adenoma
• Pancreatic G-Cell Adenoma
• Pancreatic Polypeptide Tumor
• Recurrent Adult Liver Carcinoma
• Recurrent Digestive System Neuroendocrine Tumor G1
• Recurrent Fallopian Tube Carcinoma
• Recurrent Ovarian Carcinoma
• Recurrent Pancreatic Neuroendocrine Carcinoma
• Recurrent Primary Peritoneal Carcinoma
• Recurrent Uterine Corpus Carcinoma
• Regional Digestive System Neuroendocrine Tumor G1
• Stage IIIA Fallopian Tube Cancer
• Stage IIIA Ovarian Cancer
• Stage IIIA Primary Peritoneal Cancer
• Stage IIIA Uterine Corpus Cancer
• Stage IIIB Fallopian Tube Cancer
• Stage IIIB Ovarian Cancer
• Stage IIIB Primary Peritoneal Cancer
• Stage IIIB Uterine Corpus Cancer
• Stage IIIC Fallopian Tube Cancer
• Stage IIIC Ovarian Cancer
• Stage IIIC Primary Peritoneal Cancer
• Stage IIIC Uterine Corpus Cancer
• Stage IV Fallopian Tube Cancer
• Stage IV Ovarian Cancer
• Stage IV Primary Peritoneal Cancer
• Stage IVA Uterine Corpus Cancer
• Stage IVB Uterine Corpus Cancer
• Uterine Carcinosarcoma

Interventions

BIOLOGICAL

Bevacizumab

Given IV

DRUG

Temsirolimus

Given IV

Sponsors & Collaborators

• National Cancer Institute (NCI)

  lead NIH

Principal Investigators

• Henry Pitot · Mayo Clinic

Study Design

Allocation

NA

Purpose

TREATMENT

Masking

NONE

Model

SINGLE_GROUP

Eligibility

Min Age

18 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2009-09-08

Primary Completion

2017-03-13

Completion

2017-03-13

Countries

• United States
• Canada

Study Locations